Posaconazole concentrations in human tissues after allogeneic stem cell transplantation

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4941-4943

  Blennow, Ola ^a   Eliasson, Erik ^a   Pettersson, Tommy ^a   Pohanka, Anton ^a   Szakos, Attila ^a   El Serafi, Ibrahim ^b   Hassan, Moustapha ^b   Ringdén, Olle ^a   Mattsson, Jonas ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; POSACONAZOLE; TRIAZOLE DERIVATIVE;

ADVERSE EFFECTS; ALLOTRANSPLANTATION; AUTOPSY; BLOOD; BRAIN CHEMISTRY; CHEMISTRY; GRAFT VS HOST DISEASE; HEART MUSCLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY; LIVER; LUNG; MYCOSES; PATHOLOGY;

ANTIFUNGAL AGENTS; AUTOPSY; BRAIN CHEMISTRY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY; LIVER; LUNG; MYCOSES; MYOCARDIUM; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 84905379006     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03252-14     Document Type: Article

References (15)

1. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359. http://dx.doi.org/10.1056/NEJMoa061094.
2. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347. http://dx.doi.org/10. 1056/NEJMoa061098.
3. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015. http://dx.doi.org/10.1128/AAC.00163-06.
4. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966. http://dx.doi.org/10.1128/AAC.01034-08.
5. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. 2012. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob. Agents Chemother. 56:2806-2813. http://dx.doi.org/10. 1128/AAC.05900-11.
6. Jang SH, Colangelo PM, Gobburu JV. 2010. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin. Pharmacol. Ther. 88:115-119. http://dx.doi.org/10.1038/clpt.2010.64.
7. Howard SJ, Felton TW, Gomez-Lopez A, Hope WW. 2012. Posaconazole: the case for therapeutic drug monitoring. Ther. Drug Monit. 34:72-76. http://dx.doi.org/10.1097/FTD.0b013e31823cdeac.
8. Kuipers S, Bruggemann RJ, de Sevaux RG, Heesakkers JP, Melchers WJ, Mouton JW, Verweij PE. 2011. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob. Agents Chemother. 55:3564-3566. http://dx.doi.org/10.1128/AAC.01544-10.
9. Conte JE, Jr, DeVoe C, Little E, Golden JA. 2010. Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. Antimicrob. Agents Chemother. 54:3609-3613. http://dx.doi.org/10.1128/AAC.01396-09.
10. Conte JE, Jr, Golden JA, Krishna G, McIver M, Little E, Zurlinden E. 2009. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob. Agents Chemother. 53:703-707. http://dx.doi.org/10.1128/AAC.00663-08.
11. Farowski F, Cornely OA, Vehreschild JJ, Hartmann P, Bauer T, Steinbach A, Ruping MJ, Muller C. 2010. Intracellular concentrations of posaconazole in different compartments of the peripheral blood. Antimicrob. Agents Chemother. 54:2928-2931. http://dx.doi.org/10.1128/AAC.01407-09.
12. Campoli P, Al Abdallah Q, Robitaille R, Solis NV, Fielhaber JA, Kristof AS, Laverdiere M, Filler SG, Sheppard DC. 2011. Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob. Agents Chemother. 55:5732-5739. http://dx.doi.org/10. 1128/AAC.00637-11.
13. Campoli P, Perlin DS, Kristof AS, White TC, Filler SG, Sheppard DC. 2013. Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis. J. Infect. Dis. 208:1717-1728. http://dx.doi.org/10.1093/infdis/jit358.
14. Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. 2012. Multicenter study of posaconazole therapeutic drug monitoring: exposureresponse relationship and factors affecting concentration. Antimicrob. Agents Chemother. 56:5503-5510. http://dx.doi.org/10.1128/AAC.00802-12.
15. Lignell A, Lowdin E, Cars O, Chryssanthou E, Sjolin J. 2011. Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration. Antimicrob. Agents Chemother. 55:3099-3104. http://dx.doi.org/10.1128/AAC.01671-10.